(Q43690741)

English

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma

scientific article published in April 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Athanasios Dimopoulos

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Richard E Champlin

14

object named as

Champlin R

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

15

object named as

Giralt S

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

10

object named as

Khouri I

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

author name string

Shimoni A

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Smith TL

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Aleman A

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Weber D

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Anderlini P

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Andersson B

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Claxton D

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Ueno NT

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Donato M

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Korbling M

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Alexanian R

13

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 April 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

821-828

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703007

0 references

The treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

21 January 2018

Long-term follow-up after high-dose therapy for high-risk multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

21 January 2018

Myeloablative therapy for primary resistant multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

21 January 2018

Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

21 January 2018

Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

21 January 2018

Colony growth and self renewal of plasma cell precursors in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

21 January 2018

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem cell transplantation for relapsed and primary refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

Regimen-related toxicity in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

HyperCVAD for VAD-resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive treatment of multiple myeloma and criteria for complete remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of Myelomatosis on Treatment with Prednisone and Cytostatics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703007

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1703007

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43690741&oldid=2102606891"